Frédéric Bert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Frédéric Bert has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Richard Moreau
European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain
8 shared publications - Dominique Valla
Université Paris Cité and Inserm, Paris, France
6 shared publications - François Durand
Hepatology & Liver Intensive Care, Beaujon Hospital, Clichy, France; University Paris Cité, Paris, France
5 shared publications - Catherine Paugam-Burtz
Staff Anesthesiologist
4 shared publications Marie-Hélène Nicolas-Chanoine
4 shared publicationsEstelle Marcon
3 shared publications
Latest Publications
- 1 February 2014
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 44 (2) , 76-78
Frequency and epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates susceptible to third-generation cephalosporins or to aztreonam
- 1 February 2014
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 44 (2) , 76-78
Frequency and epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates susceptible to third-generation cephalosporins or to aztreonam
- 16 December 2013
- Published by Wiley in Transplant Infectious Disease
- Vol. 16 (1) , 84-89
Risk factors associated with preoperative fecal carriage of extended‐spectrum β‐lactamase‐producing Enterobacteriaceae in liver transplant recipients
Objective: The aim of the study was to identify risk factors associated with pre‐transplant fecal carriage of extended‐spectrum β‐lactamase (ESBL)‐producing Enterobacteriaceae in liver transplant recipients.Patients and methods: Over a 3‐year period (January 2009–December 2011), 317 patients who underwent liver transplantation were screened preoperatively for fecal carriage of ESBL‐producing Enterobacteriaceae. Risk factors for fecal carriage were investigated by univariate analysis and stepwise logistic regression.Results: Of the 317 patients screened, 50 (15.7%) harbored an ESBL‐producing isolate. Previous infection with an ESBL‐producing organism had developed during the last 6 months in 20% of fecal carriers versus in none of the non‐carriers. Other variables associated with fecal carriage were a model for end‐stage liver disease score ≥25, pre‐transplant stay in the intensive care unit ≥48 h, hospital stay ≥10 days in the last 6 months, a history of spontaneous bacterial peritonitis (SBP), exposure to a β‐lactam agent in the last month, and prophylaxis with norfloxacin. Independent predictors of fecal carriage in the multivariate logistic regression model were exposure to a β‐lactam agent in the month preceding transplantation (odds ratio [OR] = 7.8, confidence interval [CI] = 4–15.5, P < 0.001), and a history of SBP (OR = 2.4, CI = 1.1–4.9, P = 0.02).Conclusions: Previous infection with an ESBL‐producing isolate, recent exposure to a β‐lactam agent, and a history of SBP are risk factors for preoperative fecal carriage of ESBL‐producing Enterobacteriaceae in liver transplant recipients. Patients at risk of fecal carriage should receive intraoperative prophylaxis and, when necessary, empiric postoperative antimicrobial treatment that includes coverage for these organisms.
- 16 December 2013
- Published by Wiley in Transplant Infectious Disease
- Vol. 16 (1) , 84-89
Risk factors associated with preoperative fecal carriage of extended‐spectrum β‐lactamase‐producing Enterobacteriaceae in liver transplant recipients
Objective: The aim of the study was to identify risk factors associated with pre‐transplant fecal carriage of extended‐spectrum β‐lactamase (ESBL)‐producing Enterobacteriaceae in liver transplant recipients.Patients and methods: Over a 3‐year period (January 2009–December 2011), 317 patients who underwent liver transplantation were screened preoperatively for fecal carriage of ESBL‐producing Enterobacteriaceae. Risk factors for fecal carriage were investigated by univariate analysis and stepwise logistic regression.Results: Of the 317 patients screened, 50 (15.7%) harbored an ESBL‐producing isolate. Previous infection with an ESBL‐producing organism had developed during the last 6 months in 20% of fecal carriers versus in none of the non‐carriers. Other variables associated with fecal carriage were a model for end‐stage liver disease score ≥25, pre‐transplant stay in the intensive care unit ≥48 h, hospital stay ≥10 days in the last 6 months, a history of spontaneous bacterial peritonitis (SBP), exposure to a β‐lactam agent in the last month, and prophylaxis with norfloxacin. Independent predictors of fecal carriage in the multivariate logistic regression model were exposure to a β‐lactam agent in the month preceding transplantation (odds ratio [OR] = 7.8, confidence interval [CI] = 4–15.5, P < 0.001), and a history of SBP (OR = 2.4, CI = 1.1–4.9, P = 0.02).Conclusions: Previous infection with an ESBL‐producing isolate, recent exposure to a β‐lactam agent, and a history of SBP are risk factors for preoperative fecal carriage of ESBL‐producing Enterobacteriaceae in liver transplant recipients. Patients at risk of fecal carriage should receive intraoperative prophylaxis and, when necessary, empiric postoperative antimicrobial treatment that includes coverage for these organisms.
- Open Access
- 1 June 2012
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 18 (6) , 908-916
Pretransplant Fecal Carriage of Extended-Spectrum β-Lactamase–producingEnterobacteriaceaeand Infection after Liver Transplant, France
Extended-spectrum β-lactamase–producing Enterobacteriaceae isolates (ESBLE) are emerging pathogens that confer resistance to antimicrobial drugs. We conducted a 10-year study in France (January 2001–April 2010) to investigate the incidence of and risk factors for ESBLE infections after liver transplant. Of 710 transplant patients screened preoperatively for ESBLE fecal carriage, 5.5% had ESBLE infection develop within 4 months after surgery; patients with pretransplant ESBLE fecal carriage were more likely to have infection develop than were noncarriers. Typing showed extensive genetic diversity, with a large predominance of CTX-M enzymes. Independent predictors of ESBLE infection were pretransplant fecal carriage, Model for End Stage Liver Disease score >25, and return to surgery. Our results indicate that the influx of preoperatively acquired ESBLE isolates into the hospital outweighs cross-transmission in the epidemiology of ESBLE infections after liver transplant. Transplant candidates should be systematically screened for carriage, and posttransplant infection in carriers should be treated with carbapenems.
- 1 June 2012
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 18 (6) , 908-916
Open AccessPretransplant Fecal Carriage of Extended-Spectrum β-Lactamase–producingEnterobacteriaceaeand Infection after Liver Transplant, France
Extended-spectrum β-lactamase–producing Enterobacteriaceae isolates (ESBLE) are emerging pathogens that confer resistance to antimicrobial drugs. We conducted a 10-year study in France (January 2001–April 2010) to investigate the incidence of and risk factors for ESBLE infections after liver transplant. Of 710 transplant patients screened preoperatively for ESBLE fecal carriage, 5.5% had ESBLE infection develop within 4 months after surgery; patients with pretransplant ESBLE fecal carriage were more likely to have infection develop than were noncarriers. Typing showed extensive genetic diversity, with a large predominance of CTX-M enzymes. Independent predictors of ESBLE infection were pretransplant fecal carriage, Model for End Stage Liver Disease score >25, and return to surgery. Our results indicate that the influx of preoperatively acquired ESBLE isolates into the hospital outweighs cross-transmission in the epidemiology of ESBLE infections after liver transplant. Transplant candidates should be systematically screened for carriage, and posttransplant infection in carriers should be treated with carbapenems.
- 28 February 2011
- Published by Wiley in Transplant Infectious Disease
- Vol. 13 (4) , 359-365
Molecular epidemiology of Escherichia coli bacteremia in liver transplant recipients
F. Bert, B. Huynh, F. Dondero, J.R. Johnson, C. Paugam‐Burtz, F. Durand, J. Belghiti, D. Valla, R. Moreau, M.‐H. Nicolas‐Chanoine. Molecular epidemiology of Escherichia coli bacteremia in liver transplant recipients. Transpl Infect Dis 2011: 13: 359–365. All rights reservedAbstract: The characteristics of Escherichia coli strains causing bacteremia in profoundly immunosuppressed patients such as transplant recipients are undefined. The phylogenetic group and the virulence genotype of 57 distinct E. coli strains that caused bacteremia in 53 liver transplant recipients were investigated, and the association of these characteristics with host factors and in‐hospital mortality was examined. Phylogenetic groups A, B1, B2, and D accounted for 39%, 10%, 25%, and 26% of the isolates, respectively. The most prevalent virulence genes were fyuA (yersiniabactin system: 70%) and iutA (aerobactin system: 63%), whereas hlyA (alpha‐hemolysin) and cnf1 (cytotoxic necrotizing factor 1) occurred in only 14% and 12% of isolates, respectively. Most virulence genes were significantly more prevalent among group B2 and D isolates, vs. group A and B1 isolates. The overall rate of in‐hospital mortality after E. coli bacteremia was 20%. Predictors of mortality included onset of bacteremia within 30 days of transplantation or during the intensive care unit stay, and non‐urinary source and cutaneous source, but not E. coli phylogenetic group or virulence profile. Compared with historical E. coli bloodstream isolates from non‐transplant patients, those from liver transplant recipients are characterized by a higher prevalence of groups A and B1 isolates and reduced virulence gene content. This finding can be explained by the severely immunocompromised status of the patients and the predominance of abdominal‐source bacteremic episodes. Time of onset and source of bacteremia, not bacterial characteristics, predict mortality.
- 28 February 2011
- Published by Wiley in Transplant Infectious Disease
- Vol. 13 (4) , 359-365
Molecular epidemiology of Escherichia coli bacteremia in liver transplant recipients
F. Bert, B. Huynh, F. Dondero, J.R. Johnson, C. Paugam‐Burtz, F. Durand, J. Belghiti, D. Valla, R. Moreau, M.‐H. Nicolas‐Chanoine. Molecular epidemiology of Escherichia coli bacteremia in liver transplant recipients. Transpl Infect Dis 2011: 13: 359–365. All rights reservedAbstract: The characteristics of Escherichia coli strains causing bacteremia in profoundly immunosuppressed patients such as transplant recipients are undefined. The phylogenetic group and the virulence genotype of 57 distinct E. coli strains that caused bacteremia in 53 liver transplant recipients were investigated, and the association of these characteristics with host factors and in‐hospital mortality was examined. Phylogenetic groups A, B1, B2, and D accounted for 39%, 10%, 25%, and 26% of the isolates, respectively. The most prevalent virulence genes were fyuA (yersiniabactin system: 70%) and iutA (aerobactin system: 63%), whereas hlyA (alpha‐hemolysin) and cnf1 (cytotoxic necrotizing factor 1) occurred in only 14% and 12% of isolates, respectively. Most virulence genes were significantly more prevalent among group B2 and D isolates, vs. group A and B1 isolates. The overall rate of in‐hospital mortality after E. coli bacteremia was 20%. Predictors of mortality included onset of bacteremia within 30 days of transplantation or during the intensive care unit stay, and non‐urinary source and cutaneous source, but not E. coli phylogenetic group or virulence profile. Compared with historical E. coli bloodstream isolates from non‐transplant patients, those from liver transplant recipients are characterized by a higher prevalence of groups A and B1 isolates and reduced virulence gene content. This finding can be explained by the severely immunocompromised status of the patients and the predominance of abdominal‐source bacteremic episodes. Time of onset and source of bacteremia, not bacterial characteristics, predict mortality.
- 30 January 2011
- Published by Wiley in Liver International
- Vol. 31 (4) , 494-498
Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites
Background and aims: Bacterial DNA (bactDNA) has been found in serum and ascitic fluid (AF) of 30-40% of hospitalized patients with cirrhosis and non-neutrocytic ascites, but its prevalence in outpatients is unknown. The aim of this prospective study was to investigate the presence of bactDNA in AF and serum among cirrhotic outpatients with non-neutrocytic ascites. Methods: Thirty-one consecutive patients with cirrhosis and non-neutrocytic ascites, who underwent therapeutic paracentesis in our outpatient clinic, were enrolled over a 13-week period. Of these patients, 13 had a single paracentesis and 18 patients had several consecutive paracenteses (2-10) over the study period. Overall, 98 serum and non-neutrocytic AF specimens were obtained and tested for the presence of bactDNA by polymerase chain reaction amplification of the 16S ribosomal RNA gene. Results: The main causes of cirrhosis were alcohol (53.5%) and hepatitis C (30%). The median MELD score was 16 and there were 54.8% Child-Pugh C patients. BactDNA was negative in all samples from 28 of the 31 patients, including 15 patients with several paracentesis. One patient had a single AF sample culture positive and bactDNA positive for Streptococcus mitis, whereas the simultaneous blood sample was negative. For each of the last two patients, DNA from Lactococcus lactis was detected in a single blood sample but not in the simultaneous AF sample. Conclusions: In contrast to that reported previously in hospitalized patients, bactDNA is rarely detected in serum and AF of outpatients with cirrhosis and non-neutrocytic ascites. © 2011 John Wiley & Sons A/S.SCOPUS: ar.jFLWINinfo:eu-repo/semantics/publishe
- 30 January 2011
- Published by Wiley in Liver International
- Vol. 31 (4) , 494-498
Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites
Background and aims: Bacterial DNA (bactDNA) has been found in serum and ascitic fluid (AF) of 30-40% of hospitalized patients with cirrhosis and non-neutrocytic ascites, but its prevalence in outpatients is unknown. The aim of this prospective study was to investigate the presence of bactDNA in AF and serum among cirrhotic outpatients with non-neutrocytic ascites. Methods: Thirty-one consecutive patients with cirrhosis and non-neutrocytic ascites, who underwent therapeutic paracentesis in our outpatient clinic, were enrolled over a 13-week period. Of these patients, 13 had a single paracentesis and 18 patients had several consecutive paracenteses (2-10) over the study period. Overall, 98 serum and non-neutrocytic AF specimens were obtained and tested for the presence of bactDNA by polymerase chain reaction amplification of the 16S ribosomal RNA gene. Results: The main causes of cirrhosis were alcohol (53.5%) and hepatitis C (30%). The median MELD score was 16 and there were 54.8% Child-Pugh C patients. BactDNA was negative in all samples from 28 of the 31 patients, including 15 patients with several paracentesis. One patient had a single AF sample culture positive and bactDNA positive for Streptococcus mitis, whereas the simultaneous blood sample was negative. For each of the last two patients, DNA from Lactococcus lactis was detected in a single blood sample but not in the simultaneous AF sample. Conclusions: In contrast to that reported previously in hospitalized patients, bactDNA is rarely detected in serum and AF of outpatients with cirrhosis and non-neutrocytic ascites. © 2011 John Wiley & Sons A/S.SCOPUS: ar.jFLWINinfo:eu-repo/semantics/publishe
- Open Access
- 1 August 2010
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 48 (8) , 2709-2714
Genetic Diversity and Virulence Profiles of Escherichia coli Isolates Causing Spontaneous Bacterial Peritonitis and Bacteremia in Patients with Cirrhosis
Among patients with cirrhosis, infections caused by Escherichia coli organisms that translocate from the gut are a frequent and severe complication. One hundred ten E. coli isolates from 110 cirrhotic patients with spontaneous bacterial peritonitis and/or spontaneous bacteremia were characterized for their phylogenetic group and virulence genotype (34 extraintestinal virulence factor genes). Genetic relatedness was investigated by enterobacterial repetitive intergenic consensus sequence type 2 (ERIC-2) PCR typing and multilocus sequence typing. Phylogenetic groups A, B1, B2, and D accounted for 24%, 4%, 48%, and 24% of the population, respectively. Overall, 68 distinct ERIC-2 profiles were encountered. Eleven clonal groups, represented by multiple isolates (2 to 11) from the same sequence type (ST) or sequence type complex, were identified. These clonal groups accounted for 54 (49%) isolates overall. Membership in one of these clonal groups was more frequent among B2 isolates than non-B2 isolates (67% versus 32%, P < 0.001). The most frequent sequence types were ST95 ( n = 13) and ST73 ( n = 8), followed by the ST14 and ST10 complexes ( n = 7). ST131 and ST69 were represented by three isolates each. Clonal group-associated isolates exhibited a greater prevalence of 11 virulence genes, including pap elements, than the other isolates. However, no association between clonal groups and host factors, type of infection, or mortality was observed. In conclusion, E. coli isolates causing spontaneous bacterial peritonitis and bacteremia in cirrhotic patients are genetically diverse. However, approximately half of the isolates belong to familiar clonal groups and exhibit extensive virulence profiles that may be associated with greater invasive potential.
- 1 August 2010
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 48 (8) , 2709-2714
Open AccessGenetic Diversity and Virulence Profiles of Escherichia coli Isolates Causing Spontaneous Bacterial Peritonitis and Bacteremia in Patients with Cirrhosis
Among patients with cirrhosis, infections caused by Escherichia coli organisms that translocate from the gut are a frequent and severe complication. One hundred ten E. coli isolates from 110 cirrhotic patients with spontaneous bacterial peritonitis and/or spontaneous bacteremia were characterized for their phylogenetic group and virulence genotype (34 extraintestinal virulence factor genes). Genetic relatedness was investigated by enterobacterial repetitive intergenic consensus sequence type 2 (ERIC-2) PCR typing and multilocus sequence typing. Phylogenetic groups A, B1, B2, and D accounted for 24%, 4%, 48%, and 24% of the population, respectively. Overall, 68 distinct ERIC-2 profiles were encountered. Eleven clonal groups, represented by multiple isolates (2 to 11) from the same sequence type (ST) or sequence type complex, were identified. These clonal groups accounted for 54 (49%) isolates overall. Membership in one of these clonal groups was more frequent among B2 isolates than non-B2 isolates (67% versus 32%, P < 0.001). The most frequent sequence types were ST95 ( n = 13) and ST73 ( n = 8), followed by the ST14 and ST10 complexes ( n = 7). ST131 and ST69 were represented by three isolates each. Clonal group-associated isolates exhibited a greater prevalence of 11 virulence genes, including pap elements, than the other isolates. However, no association between clonal groups and host factors, type of infection, or mortality was observed. In conclusion, E. coli isolates causing spontaneous bacterial peritonitis and bacteremia in cirrhotic patients are genetically diverse. However, approximately half of the isolates belong to familiar clonal groups and exhibit extensive virulence profiles that may be associated with greater invasive potential.
- Open Access
- 12 January 2010
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 16 (3) , 393-401
Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes
Bloodstream infections (BSIs) are a major cause of mortality in liver transplant recipients. The incidence, microbiology, and outcome of BSIs in the first year after liver transplantation were analyzed in 704 patients who underwent transplantation at a single center between 1997 and 2007. BSIs occurred in 205 (29.1%) of the 704 patients. Overall, 259 episodes were documented, and they resulted in an incidence rate of 36.8%. Of these episodes, 39.4%, 27.8%, 17%, and 15.8% occurred in the very early period (≤10 days after liver transplantation), the early period (days 11-30), the intermediate period (days 31-90), and the late period (days 91-365), respectively. The most frequent pathogens were Enterobacteriaceae members (41%), Staphylococcus aureus (19.8%), enterococci (13.1%), Pseudomonas aeruginosa (8.8%), and yeasts (7.1%). The median time of onset ranged from 7 days for methicillin-resistant S. aureus to 25 days for Enterobacteriaceae. Mortality at 15 days after BSIs was 16.2%. Kaplan-Meier survival curves showed that patients with BSIs had a significantly higher 1-year mortality rate than those without BSIs (28.3% versus 16.6%, P < 0.001 with the log-rank test). When the time of BSI onset was considered, 1-year mortality was significantly associated with very early and early episodes (P < 0.001) but not with intermediate and late episodes (P = 0.47). In conclusion, BSIs are frequent and early complications after liver transplantation and are mostly caused by gram-negative bacilli. A BSI in the first posttransplant month is a significant predictor of 1-year survival. Liver Transpl 16:393–401, 2010. © 2010 AASLD.
- 12 January 2010
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 16 (3) , 393-401
Open AccessMicrobial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes
Bloodstream infections (BSIs) are a major cause of mortality in liver transplant recipients. The incidence, microbiology, and outcome of BSIs in the first year after liver transplantation were analyzed in 704 patients who underwent transplantation at a single center between 1997 and 2007. BSIs occurred in 205 (29.1%) of the 704 patients. Overall, 259 episodes were documented, and they resulted in an incidence rate of 36.8%. Of these episodes, 39.4%, 27.8%, 17%, and 15.8% occurred in the very early period (≤10 days after liver transplantation), the early period (days 11-30), the intermediate period (days 31-90), and the late period (days 91-365), respectively. The most frequent pathogens were Enterobacteriaceae members (41%), Staphylococcus aureus (19.8%), enterococci (13.1%), Pseudomonas aeruginosa (8.8%), and yeasts (7.1%). The median time of onset ranged from 7 days for methicillin-resistant S. aureus to 25 days for Enterobacteriaceae. Mortality at 15 days after BSIs was 16.2%. Kaplan-Meier survival curves showed that patients with BSIs had a significantly higher 1-year mortality rate than those without BSIs (28.3% versus 16.6%, P < 0.001 with the log-rank test). When the time of BSI onset was considered, 1-year mortality was significantly associated with very early and early episodes (P < 0.001) but not with intermediate and late episodes (P = 0.47). In conclusion, BSIs are frequent and early complications after liver transplantation and are mostly caused by gram-negative bacilli. A BSI in the first posttransplant month is a significant predictor of 1-year survival. Liver Transpl 16:393–401, 2010. © 2010 AASLD.
- 28 February 2009
- Published by Elsevier in Pathologie Biologie
- Vol. 57 (1) , 56-60
Émergence d’entérocoque dépendant de la vancomycine à la suite d’un traitement par glycopeptide : cas clinique et revue
- 28 February 2009
- Published by Elsevier in Pathologie Biologie
- Vol. 57 (1) , 56-60
Émergence d’entérocoque dépendant de la vancomycine à la suite d’un traitement par glycopeptide : cas clinique et revue
- 1 November 2008
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 14 (11) , 1034-1040
Genetic background of Escherichia coli isolates from patients with spontaneous bacterial peritonitis: relationship with host factors and prognosis
- 1 November 2008
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 14 (11) , 1034-1040
Genetic background of Escherichia coli isolates from patients with spontaneous bacterial peritonitis: relationship with host factors and prognosis
- 1 May 2008
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (5) , 710-711
Viridans group streptococci causing spontaneous bacterial peritonitis and bacteremia in patients with end-stage liver disease
- 1 May 2008
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (5) , 710-711
Viridans group streptococci causing spontaneous bacterial peritonitis and bacteremia in patients with end-stage liver disease